Shifting to non-viral in vivo therapies to enhance global patient access to genetic medicines

David McCall, Senior Editor of BioInsights, talks to Hari Pujar, Chief Operating Officer, Tessera Therapeutics and Operating Partner, Flagship Pioneering, about current trends in the cell and gene therapy field aimed at addressing long-standing issues of manufacturing scalability, complexity, and high cost of goods.

Authors

Hari Pujar

Institutions

Flagship Pioneering (United States) (US)

Publication Details

Journal: Cell and Gene Therapy Insights
Published: 2024-09-27
DOI: https://doi.org/10.18609/cgti.2024.122
Primary Topic: Biotechnology and Related Fields
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Shifting to non-viral in vivo therapies to enhance global patient access to genetic medicines

Hari Pujar

Sep 27, 2024

Cell and Gene Therapy Insights

Biotechnology and Related Fields

article

Shifting to non-viral in vivo therapies to enhance global patient access to genetic medicines

Hari Pujar

September 27, 2024article en

Abstract

Cell and Gene Therapy InsightsVol. 10(8)

Flagship Pioneering (United States) (US)

Openalex Percentile: Top 58%

Biotechnology and Related Fields

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Shifting to non-viral in vivo therapies to enhance global patient access to genetic medicines — Hari Pujar · Cell and Gene Therapy Insights (2024) | TGRS Research Map | TGRS